Karyopharm Therapeutics Stock News

KPTI has been devastated by the SIENDO trial failure. The next trial's data will be read out 2 years later.

-- Conference Call Scheduled for Thursday, May 5, 2022, at 8:30 a.m. ET -- NEWTON, Mass.

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Over the past 3 months, 5 analysts have published their opinion on Karyopharm Therapeutics (NASDAQ:KPTI) stock. These analysts are typically employed by large Wall Street banks and tasked with underst

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis AbbVie, Inc. (NYSE: ABBV) announced 

NEWTON, Mass. , March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compan

Gainers: Funko FNKO +16%. Puma Biotechnology PBYI +15%

Karyopharm Therapeutics (NASDAQ:KPTI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 0 0

Karyopharm Therapeutics (KPTI) -29% after US Regulatory update on Selinexor in advanced or recurrent endometrial cancer.GoHealth GOCO -24% on expecting Q4 revenue below…

The shares of the commercial-stage pharmaceutical company, Karyopharm Therapeutics (KPTI) have lost ~28% in the pre-market Wednesday amid concerns that the company will need another…

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endome

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endometrial Cancer Karyopharm Therapeutics, Inc. (NASDAQ: KPTI ) said following discussions with the U.S. Food and Drug Administration regarding its previously planned supplemental new drug Application for selinexor in advanced or recurrent endometrial cancer , the regulator conveyed that topline results from the Phase 3 SIENDO study are unlikely to support approval. The regulator said further exploration of patients with advanced or recurrent endometrial cancer with p53 wild-type is warranted. Taking into account, the FDA''s feedback, the company intends to initiate a new study of selinexor in patients with p53 wild-type endometrial cancer and believes top-line data will be available in the first half of 2024. The stock was slumping 26.95% to $7.59 in premarket trading. Finch Pauses Phase 3 Study Of Microbiome Therapeutic CP101 Following FDA''s Clinical Hold Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) announced that it has paused enrollment in PRISM4 Phase 3 clinical trial of CP101 in recurrent C. difficile infection following the receipt of a clinical hold letter from FDA on Feb. 24, requesting additional information about Finch''s SARS-CoV-2 donor screening protocols.

Karyopharm Therapeutics Inc (NASDAQ: KPTI ) stock plunged after an update on its supplemental New Drug Application submission based on the Phase 3 SIENDO study data of selinexor as front-line maintenance therapy following chemotherapy in advanced or recurrent endometrial cancer. The cmpany received feedback that the current SIENDO study topline … Full story available on Benzinga.com